Overall, our observations suggest that adiponectin might be a valuable tool in NAFL vs. NASH stratification; however, its role as a biomarker in NAFLD can be challenged by risk-conferring genetic variants, such as the PNPLA3 c.444G allele, and can benefit from combination panels, such as the one presented comprising serum lipids. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.